A Phase 4 interventional study of Midodrine HCl and Placebo in Orthostatic Hypotension, sponsored by Shire. Completed at 13 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-08.
Sponsored by Shire (part of Takeda) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing midodrine in Hypotension, Orthostatic — none open to participants now, none under way, none of them phase 3. Midodrine · Hypotension, Orthostatic.
Among the 16 studies testing midodrine in Hypotension, Orthostatic, this one is the 11th largest by enrollment, is one of 3 that started in 2012, is one of 6 in phase 4, and was the 8th registered.
159 studies on the registry are indexed under Hypotension, Orthostatic; 35 are open to participants now.
Browse Hypotension, Orthostatic studies →None of the 16 studies testing midodrine in Hypotension, Orthostatic is open now. The open studies under Hypotension, Orthostatic, anywhere →
Midodrine: first FDA approval 1996 (PROAMATINE). What it is approved for, and how studies give it, is on its page →
Of the 23 Hypotension, Orthostatic studies recruiting now, 8 (35%) set no upper age limit and 8 (35%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 4 · Phase 3 3 · Phase 4 6
First in 1997; this study’s year is marked. 3 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 28 across 113 interventional studies indexed under Hypotension, Orthostatic.
Median enrollment 42 across the 16 interventional studies. Of the 15 that completed or were terminated, 9 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 16 have an industry lead sponsor. The 9 most frequent:
This study is registered under Shire, one of the names counted as Takeda. Under that name alone:
Shire is the lead sponsor of 351 studies on the registry; 2 are open to participants now.
Of its 48 completed or terminated interventional studies of FDA-regulated products, 48 (100%) have results posted.
Takeda has 5 studies filed under Hypotension, Orthostatic — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 16 studies testing midodrine in Hypotension, Orthostatic, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether midodrine works against the symptoms of orthostatic hypotension caused by being on a tilt table.
The efficacy of midodrine will be assessed in those subjects who have severe symptoms of orthostatic hypotension when not taking midodrine and are controlled when taking midodrine. The study will involve approximately 4 overnight stays.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Midodrine HCl
Drug: Placebo
dose at the subject's current dose level
Also known as: ProAmatine®
single dose of matching placebo
Time to Onset of Syncope/Near Syncope While on Tilt Table
After a 30-minute supine period, the table was tilted from 0-90º within 30 seconds and maintained in that position for 45 minutes or until endpoint. Subjects were monitored for near-syncopal symptoms (subject felt sufficiently dizzy, lightheaded, faint, or felt like they were about to black out and requested the table to be returned to horizontal). Such a report ended the test. Alternatively, if the investigator observed that the subject was about to lose consciousness, that also constituted an endpoint.
Time frame: 1 hour post-dose
| Milestone | Midodrine HCl (Open-label Phase) | Placebo First, Then Midodrine HCl (Randomized Phase) | Midodrine HCl First, Then Placebo (Randomized Phase) |
|---|---|---|---|
| Started | 24 | 0 | 0 |
| Completed | 20 | 0 | 0 |
| Not completed | 4 | 0 | 0 |
| Withdrew: Other | 4 | 0 | 0 |
| Milestone | Midodrine HCl (Open-label Phase) | Placebo First, Then Midodrine HCl (Randomized Phase) | Midodrine HCl First, Then Placebo (Randomized Phase) |
|---|---|---|---|
| Started | 0 | 10 | 10 |
| Completed | 0 | 9 | 10 |
| Not completed | 0 | 1 | 0 |
| Withdrew: Other | 0 | 1 | 0 |
| Milestone | Midodrine HCl (Open-label Phase) | Placebo First, Then Midodrine HCl (Randomized Phase) | Midodrine HCl First, Then Placebo (Randomized Phase) |
|---|---|---|---|
| Started | 0 | 9 | 10 |
| Completed | 0 | 9 | 10 |
| Not completed | 0 | 0 | 0 |
After a 30-minute supine period, the table was tilted from 0-90º within 30 seconds and maintained in that position for 45 minutes or until endpoint. Subjects were monitored for near-syncopal symptoms (subject felt sufficiently dizzy, lightheaded, faint, or felt like they were about to black out and requested the table to be returned to horizontal). Such a report ended the test. Alternatively, if the investigator observed that the subject was about to lose consciousness, that also constituted an endpoint.
| seconds | Placebo | Midodrine HCl |
|---|---|---|
| Time to Onset of Syncope/Near Syncope While on Tilt Table | 1105.6 ± 186.82 | 1626.6 ± 186.82 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Midodrine HCl (Open-label Phase) | — | 0/24 (0%) | 3/24 (12.5%) |
| Placebo (Randomized Phase) | — | 0/20 (0%) | 1/20 (5%) |
| Midodrine HCl (Randomized Phase) | — | 0/20 (0%) | 1/20 (5%) |
| Event | Midodrine HCl (Open-label Phase) | Placebo (Randomized Phase) | Midodrine HCl (Randomized Phase) |
|---|---|---|---|
| NauseaGastrointestinal disorders | 2/24 | 0/20 | 0/20 |
| HeadacheNervous system disorders | 2/24 | 0/20 | 0/20 |
| FatigueGeneral disorders | 0/24 | 0/20 | 1/20 |
| Back PainMusculoskeletal and connective tissue disorders | 0/24 | 1/20 | 0/20 |
| FlushingVascular disorders | 0/24 | 0/20 | 1/20 |
| Hot FlushVascular disorders | 0/24 | 0/20 | 1/20 |
Randomized Safety Analysis Set defined as all subjects who received at least 1 dose of randomized investigational product.
| Age, Continuous(years) | Placebo First, Then Midodrine HCl (Randomized Phase) | Midodrine HCl First, Then Placebo (Randomized Phase) | Total |
|---|---|---|---|
| Mean | 48.0 ± 19.52 | 42.1 ± 18.64 | 45.1 ± 18.82 |
| Age, Customized(Participants) | Placebo First, Then Midodrine HCl (Randomized Phase) | Midodrine HCl First, Then Placebo (Randomized Phase) | Total |
|---|---|---|---|
| 18 to 65 years, inclusive | 8 | 8 | 16 |
| >= 66 years | 2 | 2 | 4 |
| Sex: Female, Male(Participants) | Placebo First, Then Midodrine HCl (Randomized Phase) | Midodrine HCl First, Then Placebo (Randomized Phase) | Total |
|---|---|---|---|
| Female | 8 | 10 | 18 |
| Male | 2 | 0 | 2 |
| Region of Enrollment(Participants) | Placebo First, Then Midodrine HCl (Randomized Phase) | Midodrine HCl First, Then Placebo (Randomized Phase) | Total |
|---|---|---|---|
| United States | 10 | 10 | 20 |
Ran from May 2012 to primary completion in Jun 2013, 13 months.
Results were first posted in Jul 2014, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Midodrine